Maynard Um
-
-
-
-
-
-
-
Arcturus Therapeutics (ARCT) Reports Q3 Loss of $0.49
-
-
-
-
-
-
-
Arcturus Therapeutics (ARCT) Misses Q2 EPS by $3.55
-
-
-
-
-
-
-
Arcturus Therapeutics (ARCT) Misses Q1 EPS by 411c
-
-
-
-
-
-
-
BTIG Reiterates Buy Rating on Arcturus Therapeutics (ARCT)
-
-
-
-
-
-
-
BTIG Starts Arcturus Therapeutics (ARCT) at Buy
-
-
-
-
-
-
-
Canaccord Genuity Reiterates Buy Rating on Arcturus Therapeutics (ARCT)
-
-
-
-
-
-
-
Laidlaw Reiterates Buy Rating on Arcturus Therapeutics (ARCT)
-
401,642 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

